CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD)
Phase 3
Completed
NCT03945019
| Condition | Crohn's Disease |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Celltrion |
|---|
| Status | Completed |
|---|
| Enrollment | 396 participants |
|---|
| Interventions | CT-P13 SC (Infliximab), Placebo SC |
|---|
| Start date | Oct 28, 2019 |
|---|
| Completion date | Aug 23, 2022 |
|---|
| Results posted | Oct 23, 2023 |
|---|
Summary
This is Phase 3, Randomized, Placebo-controlled study to demonstrate superiority of CT-P13 SC over Placebo SC in Patients With Moderately to Severely Active Crohn's Disease
Percentage of Patients Achieving Clinical Remission (Based on CDAI) at Week 54
Week 54 · Participants
| CT-P13 SC 120 mg | 144 Participants |
|---|
| Placebo | 36 Participants |
|---|
Percentage of Patients Achieving Endoscopic Response (Based on Central SES-CD) at Week 54
Week 54 · Participants
| CT-P13 SC 120 mg | 118 Participants |
|---|
| Placebo | 20 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.